Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982704 | 0.86 | TSHR (0.46) | KMT2AL3MBTL1KDM4ENPC1HPGD | |
| SCHEMBL5965196 | 0.83 | TSHR (0.60) | KMT2AL3MBTL1HPGDTSHRHTT | |
| SCHEMBL5006927 | 0.82 | NAAA (0.58) | KMT2AL3MBTL1HPGDTSHRHTT | |
| SCHEMBL4983838 | 0.81 | KMT2A (0.51) | KMT2AKDM4ENPSR1HSD17B10HPGD | |
| SCHEMBL314828 | 0.81 | NAMPT (0.40) | NPC1LMNATSHRBCHEMAPT | |
| SCHEMBL3764584 | 0.81 | CTSL (0.43) | — | |
| SCHEMBL4083916 | 0.80 | BACE1 (0.38) | KMT2AKDM4EHSD17B10NPC1LMNA | |
| SCHEMBL9771503 | 0.80 | NAAA (0.60) | L3MBTL1HPGDTSHRHTTALDH1A1 | |
| SCHEMBL7585175 | 0.80 | NAAA (0.60) | L3MBTL1HPGDTSHRHTTALDH1A1 | |
| SCHEMBL11836338 | 0.80 | NAAA (0.60) | L3MBTL1HPGDTSHRHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | claimed |
| EP-2278878-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | claimed |
| WO-2009137657-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | claimed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | claimed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | claimed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | claimed |
| CN-1826106-A | Therapeutic agent for skin pigmentation | INST MED MOLECULAR DESIGN INC (JP) | 2006-08-30 | — | — | CN | claimed |
| EP-0830349-B1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | DU PONT PHARM CO (US) | 2000-03-22 | — | — | EP | claimed |
| US-5877312-A | Method for preparing alkylating agents for their use for alkylating cyclic ureas | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| EP-0830349-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| US-5637780-A | Method for preparing alkylating agents and their use for alkylating cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-10 | — | — | US | claimed |
| EP-0767770-A1 | METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996039393-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1996000708-A1 | METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-11 | — | — | WO | claimed |
| US-5231105-A | Ethylamine derivatives and antihypertensives containing the same | AJINOMOTO CO., INC. (JP) | 1993-07-27 | — | — | US | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| US-4198205-A | SULFONIC ACID-FREE DISPERSE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | KMT2A 29/4885L3MBTL1 161/4885BRD4 132/4885 |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | IAPP, APP, BACE1 | KMT2A 4111/4885L3MBTL1 4639/4885BRD4 4106/4885 |
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | KMT2A 4721/4885L3MBTL1 4793/4885BRD4 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.